Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
0.92 | (0.86) |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
— | (0.82) |
P/Operating CF |
(13.26) | (13.26) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(2.83) | (2.83) |
EV/FCF |
(2.64) | (2.64) |
Quick Ratio |
5.20 | 1.80 |
Current Ratio |
6.43 | 3.99 |
Net Debt/EBITDA |
1.65 | 0.74 |
Debt/Assets |
0.00% | 7.01% |
Debt/Equity |
0.00 | 0.13 |
Asset Turnover |
0.00 | 0.51 |
Operating CF/Net income |
1.19 | 1.80 |
Capex/Depreciation |
(2.13) | (1.37) |
Interest Coverage |
(23.85) | (78.14) |
| 0.00% | 20.40% | |
| 0.00% | (20.60%) | |
ROIC |
(141.04%) | (35.06%) |
Return on Tangible Assets |
(47.39%) | (36.60%) |
Average Days of Receivables |
96.51 | 62.72 |
Research and Development Expense of Revenue |
156.05% | 50.49% |
Selling, General and Administrative Expense of Revenue |
75.34% | 47.93% |
Intangible Assets out of Total Assets |
0.01 | 0.01 |
Share Based Compensation of Revenue |
3.47% | 3.87% |
Graham Net Nets |
0.04 | 0.04 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(12.02%) | (12.02%) |
Free Cash Flow Yield |
(39.37%) | (39.37%) |
Revenue per Share |
2.39 | 6.43 |
Operating CF per Share |
(5.25) | (4.64) |
Capex per Share |
(0.28) | (0.47) |
Free Cash Flow per Share |
(5.53) | (5.11) |
Cash per Share |
7.57 | 2.60 |
Shareholders Equity per Share |
9.65 | 6.59 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
9.65 | 6.59 |
Free Cash Flow |
(58.16) | (58.98) |
Working Capital |
90.11 | 70.98 |
Capital Expenditures |
(2.95) | (5.37) |
Net Current Asset Value |
58.77 | 30.76 |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.12 | 0.07 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.18 | 0.37 |
Cash ROIC |
(32.10%) | (50.91%) |
Accounts Receivable Turnover |
0.00 | 7.65 |
Accounts Payable Turnover |
0.00 | 5.39 |
Inventory Turnover |
0.00 | 1.23 |
Average Days of Payables |
136.57 | 65.93 |
Days of Inventory on Hand |
318.05 | 432.10 |
Average Receivables |
— | 9.70 |
Average Payables |
— | 6.03 |
Average Inventory |
— | 26.45 |
Average Assets |
— | 144.75 |
Average Common Equity |
— | (146.18) |
Columns are period end dates